SLU-PP-332 is a synthetic pan-ERR agonist (Estrogen-Related Receptors – ERRα, ERRβ, ERRγ) utilized in vitro to evaluate upregulated pathways associated with mitochondrial biogenesis and oxidative metabolism.. SLU-PP-332 binds to orphaned ERR nuclear receptors to recruit PGC-1α, driving type IIa oxidative muscle fiber switching, upregulating electron transport chain (OXPHOS) complexes, and elevating basal oxygen consumption rates in myocyte cell lines.
Price range: $54.00 through $278.00
| Quantity | Discounted Price |
|---|---|
| 3 - 5 | $51.30 |
| 6 - 8 | $50.22 |
| 9 + | $48.60 |
SLU-PP-332 is a breakthrough synthetic small-molecule pan-agonist that targets the orphan nuclear receptor family of Estrogen-Related Receptors (ERRα, ERRβ, and ERRγ). Synthesized by researchers at Saint Louis University, SLU-PP-332 serves as a first-in-class chemical probe designed to investigate nuclear-receptor-driven cellular ATP expenditure. By binding the ERR ligand-binding domain with high nanomolar potency (EC50 = 98 nM for ERRα), SLU-PP-332 triggers a robust transcriptional cascade that is associated with oxidative metabolism.
Operating independently of the classical estrogen receptor (ERα/ERβ) axis, SLU-PP-332 recruits the PGC-1α coactivator complex, modulating gene expression characteristic of Type IIa oxidative fibers and upregulating markers of mitochondrial electron transport chain components.
Batch-verified for high analytical purity at Modern Aminos, SLU-PP-332 is offered in four standardized laboratory formats:
Laboratories evaluating metabolic reprogramming, mitochondrial biogenesis, and fatty acid oxidation utilize the Pan-ERR Agonist alongside related metabolic modulators available on the site, such as SLU-PP-915, GW-501516 (Cardarine), SR-9009 (Stenabolic), and BAM15.
| Compound Name | SLU-PP-332 (Pan-ERR Agonist) |
|---|---|
| Quantity / Formats Offered | 250mcg Capsules | 500mcg Capsules | 10mg Capsules (60 Count) | 300mcg/mL Liquid Dropper (30ML) |
| Synonyms / Alt Names | SLU PP 332, Pan-ERR Agonist 332, ERRα/β/γ Small Molecule Agonist |
| CAS Number | 2762220-43-3 |
| Chemical Formula | C22H16F3NO2 |
| Molecular Weight | 383.36 g/mol |
| IUPAC Name | N-(4-(trifluoromethyl)benzyl)-N-(4-(trifluoromethyl)phenyl)acetamide |
| InChIKey | Protected Small Molecule Structure |
| SMILES Code | CC(=O)N(CC1=CC=C(C=C1)C(F)(F)F)C2=CC=C(C=C2)C(F)(F)F |
The biochemical pathways and cellular targets include:
When evaluating research efficacy and published scientific literature:
To evaluate nuclear receptor targets, metabolic pathways, and exercise-mimetic mechanisms, researchers compare SLU-PP-332 against alternative metabolic reference standards available at Modern Aminos:
| Compound / Reference | Primary Target Class | Core Mechanism of Action | Research Focus & Profile |
|---|---|---|---|
| SLU-PP-332 | Pioneer Pan-ERR Agonist (ERRα/β/γ) | Potent ERR agonism (EC50 = 98 nM for ERRα) driving PGC-1α coactivation and type IIa oxidative fiber switching | First-in-class research tool utilized to evaluate nuclear-receptor metabolic modulation, OXPHOS complex assembly, and myocyte bioenergetics |
| SLU-PP-915 | Second-Generation Pan-ERR Agonist | Balanced ERRα/β/γ agonism (EC50 ≈ 400 nM) optimized for higher resistance to enzymatic and acidic degradation during the first pass metabolism | Focuses on PK profiling, TFEB autophagic-lysosomal gene induction, and in vitro cardiac bioenergetics research |
| GW-501516 (Cardarine) | PPARδ Selective Agonist | Recruits PGC-1α via PPARδ to upregulate skeletal muscle fatty acid beta-oxidation and PDK4 expression | Focuses on PPARδ nuclear receptor signaling, fatty acid transport (FAT/CD36), and glycogen sparing in myocytes |
| SR-9009 (Stenabolic) | Rev-Erbα / Rev-Erbβ Agonist | Modulates circadian metabolic gene expression and suppresses hepatic lipogenesis through Rev-Erb activation | Focuses on circadian rhythm alignment, mitochondrial density expansion, and basal metabolic rate regulation |
Yes, Modern Aminos is a highly trusted vendor for high-purity research chemicals and novel metabolic reference standards. Every batch undergoes strict third-party analytical testing (including HPLC and Mass Spectrometry) to verify minimum 98%+ chemical purity, correct molecular weight (383.36 g/mol), and complete absence of heavy metals or synthesis impurities.
As a synthetic small-molecule pan-agonist of Estrogen-Related Receptors (ERRs), tt binds all three ERR isoforms with nanomolar affinity: ERRα (EC50 = 98 nM), ERRβ (EC50 = 230 nM), and ERRγ (EC50 = 430 nM).
Estrogen-Related Receptors (ERRs) regulate metabolic gene expression. As an ERR pan-agonist, it stimulates specific target genes (including Pdk4 and Slc25a20) in resting cell models. This upregulates cellular pathways linked to mitochondrial biogenesis and oxidative metabolism without requiring mechanical stimuli.
In myocyte cultures, SLU-PP-332 recruits PGC-1α to induce gene expression in profiles characteristic of oxidative (Type IIa) muscle phenotypes, increasing mitochondrial electron transport chain subunits and boosting lipid beta-oxidation.
Modern Aminos provides SLU-PP-332 in four standardized laboratory formats: 250mcg dry-fill capsules, 500mcg dry-fill capsules, 10mg dry-fill capsules (all 60 count bottles), and a 300mcg/mL liquid dropper solution in a 30ML amber glass bottle.
SLU-PP-332 is the pioneer pan-ERR agonist featuring high in vitro potency for ERRα (98 nM). SLU-PP-915 is a second-generation analog chemically modified to improve resistance to enzymatic and acidic degradation in systemic metabolic models while maintaining pan-ERR activity.
Modern Aminos utilizes High-Performance Liquid Chromatography (HPLC) to confirm purity profiles exceeding 98% and Mass Spectrometry (MS) to verify exact molecular weight (383.36 g/mol) and structural identity prior to batch release.
Capsule bottles and liquid dropper vials should be stored tightly sealed in a cool, dry environment (15°C to 25°C) protected from direct sunlight and heat. Stored under controlled room temperature to maintains full chemical stability throughout its designated shelf life.
Disclaimer: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.
By purchasing this product, you confirm that:
Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.
